Skip to content

Clinical trials

Pain trials in Brazil with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pain Phase: Not applicable Country / region: Brazil Clear all

119 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20051
20071
20084
20094
20105
20118
20123
20135
201410
20158
20168
201716
20188
20193
20202
20216
20223
20236
20247
20255
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed71
Unknown status32
Not yet recruiting5
Recruiting3
Enrolling by invitation2
Suspended2
Terminated2
Withdrawn1
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of Sao Paulo18
Federal University of São Paulo11
University of Nove de Julho7
University of Sao Paulo General Hospital7
Hospital de Clinicas de Porto Alegre6
Universidade Federal do Para5
Centro Universitário Augusto Motta4
Universidade Federal de Sao Carlos4
Federal University of the Valleys of Jequitinhonha and Mucuri3
Universidade Federal de Pernambuco3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pain119
Low Back Pain10
Fibromyalgia9
Edema7
Breast Neoplasms6
Chronic Pain5
Trismus5
Osteoarthritis, Knee4
Agnosia3
Back Pain3

Trials

Showing 1 to 25 of 119. Each trial links to its page on Pharma Observatory.

19 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.